Infectious complications in lupus nephritis treatment: a systematic review and meta-analysis

Abstract

Objectives

Infection is an important concern in lupus nephritis treatment, but few studies have focused on this complication. Available data suggest marked variation in occurrence and outcome. This meta-analysis and review aims to provide an overview of infective complications, focusing on the risk factors and outcomes.

Methods

Original articles on lupus nephritis Class III/IV/V published in the period January 1980 to December 2016 were identified from the Pubmed/Medline electronic database. Meta-analysis of randomized controlled trials was performed to investigate total and serious infections at different phases of treatment and their associated factors. A descriptive review that included all studies was also performed, providing details on the types of infection, infection-related mortality, and potential impact of different eras on infection rates.

Results

A total of 56 studies (32 randomized controlled trials) were included. The incidence rates of overall and serious infections were higher during the induction than maintenance phase of therapy, with serious infections occurring at 8.2–50 and 3.5 per 100 patient-years, respectively. Recent data, predominantly from Asia, suggested lower rates of overall infections with induction regimens that included tacrolimus compared with mycophenolate (risk ratio 0.50, 95% confidence interval 0.33–0.76, p = 0.001). Mycophenolate as induction treatment was associated with lower overall infection risks than cyclophosphamide in non-Asians (risk ratio 0.60, 95% confidence interval 0.48–0.75, p < 0.001). The rates of serious infections were 4.1–25% in Asian and 4.4–8.5% in non-Asian countries; with infection-related mortality rates of 0–6.7% in Asian, compared to 0–2.1% in non-Asian locations.

Conclusions

Infection remains a serious complication during treatment of lupus nephritis, but the reported rates and outcomes varied markedly. Mycophenolate was associated with lower infection risk than cyclophosphamide in non-Asians. Infection-related deaths appeared more common in Asian patients.

Keywords

Lupus nephritis infections cyclophosphamide mycophenonate mofetil tacrolimus Asia

Get full access to this article

View all access options for this article.

References

Feldman

Hiraki

Winkelmayer

et al.

Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis. Arthritis Rheumatol 2015; 67(6): 1577–1585.

Singh

Hossain

Kotb

Wells

. Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis. BMC Med 2016; 14(1): 137.

Bernatsky

Boivin

Joseph

et al.

Mortality in systemic lupus erythematosus. Arthritis Rheum 2006; 54(8): 2550–2557.

Cervera

Khamashta

Font

et al.

Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine 2003; 82(5): 299–308.

Isenberg

Appel

Contreras

et al.

Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford, UK) 2010; 49(1): 128–140.

Korbet

Schwartz

Evans

Lewis

Collaborative Study

. Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol 2007; 18(1): 244–254.

Mohan

Radhakrishnan

. Geographical variation in the response of lupus nephritis to mycophenolate mofetil induction therapy. Clin Nephrol 2011; 75(3): 233–241.

Zhu

Chen

Lin

Ren

et al.

Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol, Dial, Transplant 2007; 22(7): 1933–1942.

Henderson

Masson

Craig

et al.

Treatment for lupus nephritis. Cochrane Database Syst Rev 2012; 12: CD002922.

10.

Flanc

Roberts

Strippoli

Chadban

Kerr

Atkins

. Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2004; 43(2): 197–208.

11.

Lee

Song

. Relative efficacy and safety of tacrolimus, mycophenolate mofetil, and cyclophosphamide as induction therapy for lupus nephritis: a Bayesian network meta-analysis of randomized controlled trials. Lupus 2015; 24(14): 1520–1528.

12.

Higgins

Altman

Gotzsche

et al.

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.

13.

R Core Team. (2017). R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. https://www.R-project.org/.

14.

Viechtbauer

. Conducting meta-analyses in R with the metafor package. J Stat Software 2010; 36(3): 1–48.

15.

Schwarzer

. meta: An R package for meta-analysis. R News 2007; 7(3): 40–45.

16.

Zeher

Doria

Lan

et al.

Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis. Lupus 2011; 20(14): 1484–1493.

17.

Ong

Hooi

Lim

et al.

Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology 2005; 10(5): 504–510.

18.

Ginzler

Dooley

Aranow

et al.

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. New Engl J Med 2005; 353(21): 2219–2228.

19.

Appel

Contreras

Dooley

et al.

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20(5): 1103–1112.

20.

El-Shafey

Abdou

Shareef

. Is mycophenolate mofetil superior to pulse intravenous cyclophosphamide for induction therapy of proliferative lupus nephritis in Egyptian patients? Clin Exp Nephrol 2010; 14(3): 214–221.

21.

Ren

Zhang

et al.

Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol, Dial, Transplant 2012; 27(4): 1467–1472.

22.

Chan

Tang

et al.

Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. New Engl J Med 2000; 343(16): 1156–1162.

23.

Mok

Ying

Yim

et al.

Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Ann Rheum Dis 2016; 75(1): 30–36.

24.

Chen

Tang

Liu

et al.

Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial. Am J Kidney Dis 2011; 57(2): 235–244.

25.

Liu

Zhang

Liu

et al.

Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med 2015; 162(1): 18–26.

26.

Bao

Liu

Xie

Zhang

. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol 2008; 19(10): 2001–2010.

27.

Furie

Nicholls

Cheng

et al.

Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol 2014; 66(2): 379–389.

28.

Mysler

Spindler

Guzman

et al.

Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum 2013; 65(9): 2368–2379.

29.

Askanase

Byron

et al.The ACCESS Trial Group. . Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study. Arthritis Rheumatol 2014; 66(11): 3096–3104.

30.

Austin

HA III

Illei

Braun

Balow

. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 2009; 20(4): 901–911.

31.

Miyasaka

Kawai

Hashimoto

. Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study. Mod Rheumatol 2009; 19(6): 606–615.

32.

Ayodele

Okpechi

Swanepoel

. Long-term renal outcome and complications in South Africans with proliferative lupus nephritis. Int Urol Nephrol 2013; 45(5): 1289–1300.

33.

Dhir

Aggarwal

Lawrence

Agarwal

Misra

. Long-term outcome of lupus nephritis in Asian Indians. Arthritis Care Res 2012; 64(5): 713–720.

34.

Mitwalli

Al Wakeel

Hurraib

et al.

Comparison of high and low dose of cyclophosphamide in lupus nephritis patients: a long-term randomized controlled trial. Saudi J Kidney Dis Transplant 2011; 22(5): 935–940.

35.

Chan

Tse

Tang

Mok

. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16(4): 1076–1084.

36.

Liang

Yang

et al.

Clinical predictors of recovery and complications in the management of recent-onset renal failure in lupus nephritis: a Chinese experience. J Rheumatol 2004; 31(4): 701–706.

37.

Rivera

Merida

Illescas

et al.

Mycophenolate in refractory and relapsing lupus nephritis. Am J Nephrol 2014; 40(2): 105–112.

38.

Contreras

Pardo

Leclercq

et al.

Sequential therapies for proliferative lupus nephritis. New Engl J Med 2004; 350(10): 971–980.

39.

Pohl

Lan

Berl

. Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. Ann Intern Med 1991; 114(11): 924–929.

40.

Rovin

Furie

Latinis

et al.

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012; 64(4): 1215–1226.

41.

Austin

HA III

Klippel

Balow

et al.

Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. New Engl J Med 1986; 314(10): 614–619.

42.

Illei

Austin

Crane

et al.

Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135(4): 248–257.

43.

Gourley

Austin

HA III

Scott

et al.

Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 996; 125(7): 549–557.

44.

Liu

Jiang

Wang

Yao

. Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials. Drugs 2012; 72(11): 1521–1533.

45.

Faul

Donnelly

Merscher-Gomez

et al.

The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008; 14(9): 931–938.

46.

Wang

et al.

Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study. Lupus 2012; 21(9): 1025–1035.

47.

Zhang

Liu

Zhou

et al.

Multitarget therapy for maintenance treatment of lupus nephritis. J Am Soc Nephrol 2017; 28(12): 3671–3678.

48.

Gaitonde

Pathan

Sule

Mittal

Joshi

. Efficacy of isoniazid prophylaxis in patients with systemic lupus erythematosus receiving long term steroid treatment. Ann Rheum Dis 2002; 61(3): 251–253.

49.

Stern

Green

Paul

Vidal

Leibovici

. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database of Systematic Reviews 2014; 10: Art. No.: CD005590. DOI: 10.1002/14651858.CD005590.pub3.

50.

Moroni

Quaglini

Gallelli

Banfi

Messa

Ponticelli

. Progressive improvement of patient and renal survival and reduction of morbidity over time in patients with lupus nephritis (LN) followed for 20 years. Lupus 2013; 22(8): 810–818.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.10 MB

0.06 MB

0.03 MB